Patents Assigned to Amylin Pharmaceuticals, LLC
  • Patent number: 8329648
    Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: December 11, 2012
    Assignee: Amylin Pharmaceuticals, LLC
    Inventors: Mark Fineman, Leigh MacConell, Kristin Taylor
  • Patent number: 8309522
    Abstract: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
    Type: Grant
    Filed: February 4, 2008
    Date of Patent: November 13, 2012
    Assignee: Amylin Pharmaceuticals, LLC
    Inventors: Kevin D. Laugero, Michael R. Hanley, Christine M. Mack, David G. Parkes, Paul McGonigle
  • Patent number: 8299024
    Abstract: Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce cell regeneration.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: October 30, 2012
    Assignees: Amylin Pharmaceuticals, LLC, Eli Lilly and Company
    Inventors: Alex Rabinovitch, Wilma L. Suarez-Pinzon
  • Patent number: 8288338
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: October 16, 2012
    Assignee: Amylin Pharmaceuticals, LLC
    Inventors: Andrew A. Young, Sunil Bhavsar, Bronislava Gedulin
  • Patent number: 8278267
    Abstract: Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: October 2, 2012
    Assignee: Amylin Pharmaceuticals, LLC
    Inventors: Christian Weyer, Kevin D. Laugero, Christine M. Mack, David G. Parkes
  • Patent number: 8273713
    Abstract: Methods and compositions are disclosed to treat metabolic disorders such as obesity, diabetes, and increased cardiovascular risk comprising administering a therapeutically effective amount of a PYY or a PYY agonist.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: September 25, 2012
    Assignee: Amylin Pharmaceuticals, LLC
    Inventors: Richard A. Pittner, Andrew A. Young, James R. Paterniti, Jr.